Latest Conference Coverage

Success of Ravulizumab Through the Phase 3 CHAMPION-NMOSD Trial: Sean Pittock, MD

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]

Efficacy of Remote Neuromodulation for Migraine Prevention: Stewart J. Tepper, MD

At the 2023 AAN Annual Meeting, the professor of neurology at the Geisel School of Medicine at Dartmouth talked about the effectiveness of a remote electrical neuromodulation device that offers potential relief for both episodic and chronic migraine. [WATCH TIME: 3 minutes]

Investigating Losmapimod in Phase 2 Trial for Facioscapulohumeral Muscular Dystrophy

Leo H. Wang, MD, PhD, FAAN, associate professor of neurology, University of Washington Medical Center, talked about the phase 2 study of losmapimod for facioscapulohumeral muscular dystrophy presented at the 2023 AAN Annual Meeting.

Utilizing More Effective, Descriptive End Points in Multiple Sclerosis Trials: Michael Barnett, PhD, MBBS, FRACP

Neuroprotection and Inflammation Reduction, Improvement in Biomarkers From ACT-AD Study: Hans J. Moebius, MD, PhD

At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]

Effects of Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis: Michael Barnett, PhD, MBBS, FRACP

The senior academic at the University of Sydney provided perspective on the promising findings of the phase 2 VISIONARY-MS study of CNM-Au8 in relapsing multiple sclerosis. [WATCH TIME: 6 minutes]

Moving Beyond Symptom Management, Using Antiseizure Medicines and Disease Modifying Therapies: Jacqueline French, MD

The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation spoke about her talk on new treatments for drug resistant epilepsy given at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Detecting Parkinson Disease at Early Stages With Alpha-Synuclein Amplification Assay: Russell Lebovitz, MD, PhD

Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhD

Effectiveness of Zavegepant in Treating Migraine With and Without Aura: Timothy Smith, MD

The chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]

Migraine Vaccine Shows Comparable Efficacy to Monoclonal Antibodies for Migraine Relief: Jean-Cosme Dodart, PhD

The senior vice president of research at Vaxxinity talked about research for a potential vaccine for migraine prevention presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

AOC 1001 as a Potential Treatment for Myotonic Dystrophy Type 1

Nicholas Johnson, MD, MSci, FAAN, division chief of neuromuscular disorders and vice chair of research, Virginia Commonwealth University, provided insight on promising phase 1/2 data of AOC 1001 in myotonic dystrophy type 1.

Narrowing Down Effective Medications, Classes of Treatments for Migraine: Chia-Chun Chiang, MD

The associate professor of neurology at Mayo Clinic Rochester discussed specific findings from a simultaneous comparison of migraine medications in which certain treatments and classes were more effective. [WATCH TIME: 3 minutes]

Enhancing Alzheimer Disease Clinical Trials With Predictive Machine Learning Models: Ali Ezzati, MD

The assistant professor in the department of neurology at the Albert Einstein College of Medicine and Montefiore Medical Center talked about predictive models in Alzheimer disease for clinical trials. [WATCH TIME: 5 minutes]

Insights on Pridopidine From the HEALEY ALS Platform Trial

Melanie Leitner, PhD, consultant and founder of Accelerating NeuroVentures, talked about the findings from regimen D of the HEALY ALS platform trial assessing pridopidine.

Intrathecal Mesenchymal Stem Cells as a Potential Treatment for Progressive Multiple Sclerosis: Saud A. Sadiq, MD, FAAN

The director and chief research scientist at Tisch MS Research Center of New York talked about a phase 2 data study on stem cell treatment for multiple sclerosis that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

Endovascular Treatment Improves Functional Outcomes for Acute Basilar Artery Occlusion

Although it showed better functional outcomes, endovascular thrombectomy for the treatment of stroke because of basilar-artery occlusion was associated with procedural complications and intracerebral hemorrhage.

ENSEMBLE Study Results, Ocrelizumab as Promising Early Treatment for MS: Robert A. Bermel, MD

The director of the Mellen Center for MS at Cleveland Clinic talked about the ENSEMBLE study results that were presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Endovascular Thrombectomy Shows Better Functional Outcomes Than Medical Care for Ischemic Stroke

Although the incidence of symptomatic intracranial hemorrhage was low, 18% of the patients in the endovascular thrombectomy group had complications associated with the procedure.

Diagnostic Criteria, Phenotypes and Epidemiology of Autoimmune Encephalitis: Divyanshu Dubey, MBBS

The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]

Intrathecal Mesenchymal Stem Cell-Neural Progenitor Therapy Shows Therapeutic Response in Subgroups of Progressive MS

In a subgroup of individuals with secondary progressive MS, 50% of patients on mesenchymal stem cell-neural progenitor therapy improved muscle strength compared with 33% of those on placebo.

Evolving Landscape of Pediatric Neurology: Erika Fullwood Augustine, MD, MS

The associate chief science officer at Kennedy Krieger Institute shared thoughts on the state of pediatric neurology and the significance of being named winner of the Sydney Carter Award. [WATCH TIME: 3 minutes]

Recognizing Symptoms and Causes of Rapidly Progressive Dementia: Gregory Day, MD, MSc, MSCI, FAAN

The neurologist at Mayo Clinic in Jacksonville Florida provided perspective on his talk given at the 2023 AAN annual meeting on rapidly progressive dementia. [WATCH TIME: 6 minutes]

Combination of Cipaglucosidase Alfa and Miglustat Shows Sustained Motor and Respiratory Function in Pompe Disease

After 48 months of follow up, cipaglucosidase alfa/miglustat in cohorts of ambulatory patients with Pompe disease had an overall safety profile similar to the approved enzyme replacement therapy.

Using Large-Scale Data, AI to Assess Effective Migraine Treatment Options: Chia-Chun Chiang, MD

The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]

Investigational Agent ALXN1840 Demonstrates Superior Efficacy to Standard of Care in Wilson Disease

Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.

Subgroup Analyses of Ravulizumab Demonstrates Effectiveness Across Patient Populations: Michael Levy, MD, PhD

The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Remote Electrical Neuromodulation Displays Superiority in Significantly Reducing Migraine Days

Presented at the 2023 AAN Annual Meeting, remote electrical neuromodulation demonstrated itself as an effective and safe treatment for the prevention of migraine when applied every other day.

Cenobamate as a Promising Treatment for Patients With Epilepsy: William E. Rosenfeld, MD, FAAN, FAES

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

NeuroVoices: John Hey, PhD, on ALZ-801’s Impact on Alzheimer Biomarkers, P-Tau181

The chief scientific officer at Alzheon discussed new, positive 12-month findings on ALZ-801, an investigational agent in development for patients with early-stage Alzheimer disease.